Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory by Yonamine, Caio Yogi et al.
  Universidade de São Paulo
 
2016
 
Resveratrol improves glycemic control in
insulin-treated diabetic rats: participation of the
hepatic territory
 
 
Nutrition & Metabolism. 2016 Jun 29;13(1):44
http://www.producao.usp.br/handle/BDPI/50375
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Clínica Médica - FM/MCM Artigos e Materiais de Revistas Científicas - ICB/BMB
RESEARCH Open Access
Resveratrol improves glycemic control in
insulin-treated diabetic rats: participation of
the hepatic territory
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Abstract
Background: Resveratrol is a natural polyphenol that has been proposed to improve glycemic control in diabetes,
by mechanisms that involve improvement in insulin secretion and activity. In type 1 diabetes (T1D), in which insulin
therapy is obligatory, resveratrol treatment has never been investigated. The present study aimed to evaluate
resveratrol as an adjunctive agent to insulin therapy in a T1D-like experimental model.
Methods: Rats were rendered diabetic by streptozotocin (STZ) treatment. Twenty days later, four groups of animals
were studied: non-diabetic (ND); diabetic treated with placebo (DP); diabetic treated with insulin (DI) and diabetic
treated with insulin plus resveratrol (DIR). After 30 days of treatment, 24-hour urine was collected; then, blood, soleus
muscle, proximal small intestine, renal cortex and liver were sampled. Specific glucose transporter proteins were
analyzed (Western blotting) in each territory of interest. Solute carrier family 2 member 2 (Slc2a2), phosphoenolpyruvate
carboxykinase (Pck1) and glucose-6-phosphatase catalytic subunit (G6pc) mRNAs (qPCR), glycogen storage and sirtuin 1
(SIRT1) activity were analyzed in liver.
Results: Diabetes induction increased blood glucose, plasma fructosamine concentrations, and glycosuria. Insulin
therapy partially recovered the glycemic control; however, resveratrol as adjunctive therapy additionally improved
glycemic control and restored plasma fructosamine concentration to values of non-diabetic rats. Resveratrol did not
alter the expression of the glucose transporters GLUT2 and SGLT1 in the intestine, GLUT2 and SGLT2 in kidney and
GLUT4 in soleus, suggesting that fluxes of glucose in these territories were unaltered. Differently, in liver, resveratrol
promoted a reduction in Slc2a2, Pck1, and G6pc mRNAs, as well as in GLUT2 protein (P < 0.05, DIR vs. DI); besides, it
increased (P < 0.01, DIR vs. DI) the hepatic glycogen content, and SIRT1 protein.
Conclusions: Resveratrol is able to improve glycemic control in insulin-treated T1D-like rats. This effect seems not to
involve changes in glucose fluxes in the small intestine, renal proximal tubule, and soleus skeletal muscle; but to be
related to several changes in the liver, where downregulation of Slc2a2/GLUT2, Pck1, and G6pc expression was observed,
favoring reduction of glucose production and efflux. Besides, resveratrol increased SIRT1 nuclear protein content in liver,
which may be related to the observed gene expression regulations.
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Background
Diabetes mellitus (DM) is an epidemic metabolic disease
growing at exponential rate. Type 2 DM (T2D) accounts
for around 90 % of all diabetes subjects, but type 1 DM
(T1D) incidence is also increasing worldwide [1]. The
failure of pancreatic beta cells to produce insulin, and
the impairment of insulin action, play a central role in
the disruption of glycemic homeostasis, leading to
hyperglycemia, a hallmark of DM [2]. DM shows a
complex scenario, including complications derived from
the macro and microangiopathy development [3]. At
present, optimized glucose control is recognized as the
best approach to reduce the risk of diabetes chronic
complications [4].
Insulin sensitizer agents, which could improve gly-
cemic control, have been extensively investigated for
treatment of T2D. However, the recent finding of insulin
resistance in T1D patients [5, 6] has driven attention to
their use as adjunctive agents to insulin therapy [7–10].
Beyond several compounds tested to treat DM, resvera-
trol gained much attention in recent years [11]. Resvera-
trol is a natural polyphenol that belongs to stilbene
class, widely found in several plant species, especially in
grapes and blueberries [12]. It is capable of activating
NAD+ -dependent histone deacetylase sirtuin 1 (SIRT1),
the main mechanism related to its effects [11]. Numer-
ous studies report a wide diversity of healthy-related
properties of resveratrol, including management of dis-
eases such as cancer, Alzheimer, obesity and DM [13].
Regarding the potential effects of resveratrol in DM
treatment, a glycemia-lowering effect was described in
normal rats and mice [14, 15], high-fat fed mice [16],
T2D db/db mice [17], and T2D humans as well [11]. In
these conditions, a reduction in insulin resistance has
been described, and in some of the experimental models,
a concomitant increase in insulin secretion was also ob-
served [15, 17]. However, it remains unknown whether
improved glycemic control was cause or consequence of
improved beta-cell function. Curiously, there are some
reports suggesting that resveratrol could also decrease
hyperglycemia in streptozotocin (STZ)-induced diabetic
rats [14, 18–20], an insulinopenic model of DM consid-
ered a T1D-like condition, in which amelioration of pan-
creatic insulin secretion would be unexpected.
Glycemic homeostasis results from an orchestrated
regulation of territorial glucose fluxes, which includes
flows into and out of the extracellular/blood compart-
ments [21, 22]. Some of these fluxes of glucose are
highly variable, even being tightly regulated, and they
can alter blood glucose quite rapidly. These include glu-
cose fluxes to blood from the intestine (postprandial ab-
sorption), liver (glucose production) and kidney (glucose
reabsorption); and also glucose fluxes from blood to
liver, skeletal muscle and adipose tissue, highlighting
these fluxes as the most variable and regulatable
[21–23]. All these fluxes involve several distinct and com-
plex mechanisms, and, in each territory, one or more glu-
cose transporter isoforms play a key role [24, 25]. In
epithelial cells of proximal intestine and in renal proximal
tubule, sodium glucose cotransporter 1 and 2 (SGLT1 and
SGLT2), respectively, uptake glucose at the luminal mem-
brane; whereas the facilitative glucose transporter 2
(GLUT2) effluxes glucose into the interstitium/blood side
[24, 25]. In hepatocytes, GLUT2 performs a bidirectional
flux of glucose, accordingly to the substrate concentration
gradient, which is critical for cellular glucose production
[23]. Finally, the glucose uptake by muscle and adipose
tissue occurs through the GLUT4, which can be acutely
translocated to the plasma membrane in response to
insulin [24, 26].
Most of these glucose fluxes have been proposed to be
altered in DM, and that would involve changes in the
expression of specific glucose transporters. On the other
hand, regulation of some glucose transporters has been
proposed as important targets for the development of pre-
ventive and therapeutic approaches for DM [23, 26, 27].
In this context, resveratrol could modulate the expression
of some GLUTs/SGLTs spread in many peripheral terri-
tories, and that might participate in its effect on glycemic
homeostasis.
So far, the beneficial effects of resveratrol have been
shown in rodent models of T2D, in T2D patients, and in
untreated T1D-like rats. This latter condition does not
contribute to the investigation of the potential benefits
of resveratrol for T1D patients, because it does not
reflect their real life situation, since they necessarily re-
quire insulin therapy. Thus, the present study aimed to
investigate if resveratrol could act as an adjunctive agent
to insulin therapy in a T1D-like experimental model. For
that, insulin-treated STZ-rats were additionally treated
with resveratrol; glycemic control and expression of
glucose transporters in distinct territories involved on
glycemic homeostasis were evaluated. Besides, because
the hepatic GLUT2 expression was highly altered, glu-
cose metabolism markers involved in the regulation of
glucose fluxes and SIRT1 activity were also investigated
in this territory.
Methods
Animals and treatments
Forty 60-day old male Wistar rats weighing 250 g were
obtained from the Animal Center of the Institute of
Biomedical Sciences, University of São Paulo. The
animals were housed in a room kept at constant
temperature (23 ± 2 °C), in light/dark cycle (12/12 h),
receiving standard rat chow (Nuvilab CR1; Nuvital
Nutrients S/A, Colombo, Paraná, Brazil) and tap water
ad libitum.
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At 75 days of life, animals were rendered diabetic
by intravenous injection of STZ (Sigma Chemical Co,
St Louis, MO, EUA) at a dose of 50 mg/Kg of body
weight, solubilized in citrate buffer (pH 4.5); and control
rats were injected with citrate buffer. The procedure was
performed in halothane (Tanohalo®, Cristália, Itapira, SP,
Brazil) anaesthetized animals.
Twenty days later (95-day old rats), a trial was per-
formed to evaluate the efficiency of diabetes induction,
and animals with a blood glucose concentration above
300 mg/dL (measured at 10:00 AM, after 4-hour food
deprivation) were included in the study. Immediately,
the animals were separated into four groups: non-
diabetic control (ND); diabetic treated with 0.9 % NaCl
as placebo (DP); diabetic treated with 5 U/day NPH in-
sulin (Humulin®, Eli Lilly and Company, Indianapolis,
IN, USA) (DI) and diabetic treated with 5 U/day NPH
insulin plus 10 mg/Kg body weight resveratrol (Sigma-
Aldrich, St. Louis, USA) (DIR). Insulin and resveratrol
were subcutaneously and intraperitoneally injected, re-
spectively. The treatments were conducted during thirty
days, totalizing 50 days of diabetes duration. The experi-
mental protocol was approved by the Ethical Committee
for Animal Research of the Institute of Biomedical
Sciences, University of São Paulo (#194/2013).
Sampling collection
At the end of the treatments, 24-hour urine was collected.
Then, at 10:00 AM (after 4-hour food deprivation), the an-
imals were anaesthetized with 60 mg/Kg sodium thiopen-
tal (Cristália®, Itapira, São Paulo, Brazil), and tail blood
samples were collected for glucose concentration analysis.
After, soleus muscle, liver, kidney and proximal small in-
testine were sampled and storage at –70 °C for further
analysis. Additionally, immediately after liver sampling,
blood was collected from the inferior vena cava, for fruc-
tosamine concentration analyzes in plasma. Kidneys were
removed, and outside cortex slices were excised, as previ-
ously described [28].
Plasma fructosamine, blood glucose, and 24-hour urinary
glucose excretion
Plasma fructosamine concentration was measured by a
kinetic-colorimetric assay (Frutosamina, Labtest, Lagoa
Santa, MG, Brazil) and blood glucose concentration by a
glucometer (Accu-Check Active Basel, Switzerland). The
24-hour urine volume was measured, a sample was
centrifuged at 1,000 g (10 min), and the supernatant
was used to measure glucose concentrations by an
enzymatic-colorimetric assay (Glicose Liquiform Labtest,
Lagoa Santa, MG, Brazil); the results were expressed as
24-hour glucose excretion, taking into account the total
urinary volume.
Hepatic glycogen content
Hepatic glycogen content was measured as previously
described [29]. Briefly, 250 mg of liver tissue were treated
for glycogen breakdown, and thus, glycogen was pelleted by
ethanol/Na2SO4 treatment. After hydrolysis, glycogen con-
tent was calculated based on the glucose concentrations in
the samples, measured by an enzymatic-colorimetric assay
(Glicose Liquiform, Labtest, Lagoa Santa, MG, Brazil).
mRNA quantification by real-time polymerase chain
reaction (qPCR)
Total RNA was isolated from approximately 100 mg of
soleus skeletal muscle, and liver. The samples were proc-
essed accordingly to TRIzol® Reagent manufacturer speci-
fications (Invitrogen, Carlsbad, CA, USA). The amount of
total RNA in each sample was determined using a spec-
trophotometer (Gene Quant, PHARMACIA BIOTECH -
Biochrom, Cambridge, UK). The integrity of RNA was
verified by the presence of 18S and 28S bands and con-
firmed by a 1.5 % denaturant agarose gel electrophoresis
exposed to ultra-violet light (Epi Chemi II Darkroom,
UVP BioImaging Systems, Upland, California, CA, USA).
The reverse transcriptase (RT) reaction was performed
from 2 μg of total RNA, adding to the reaction: oligo dT
(100 μg/mL), 10 mM of each dNTP, 5X First-Strand buffer
and 2 μl (200 U/μl) of M-MLV Reverse Transcriptase
(Promega, Madison, WI). The conditions of RT reaction
were 65 °C for 10 min, followed by 37 °C for 60 min, and
95 °C for 10 min. The qPCR amplification was performed
using Taqman® PCR master mix kit (Applied Biosystems
Inc., Foster City, CA, USA) and carried out with StepOne
Plus Instrument (Applied Biosystems Inc., Foster City,
CA, USA). The PCR conditions were 1 cycle of 10 min at
95 °C and 40 cycles of 30 s at 95 °C, 60 s at 60 °C and 60 s
at 72 °C. The method of 2 –ΔΔCt was adopted for analysis.
The genes analyzed were: solute carrier family 2 member 4
(Slc2a4), solute carrier family 2 member 2 (Slc2a2), phos-
phoenolpyruvate carboxykinase 1 (Pck1), glucose-6-
phosphatase catalytic subunit (G6pc). The reference gene
used was beta-2-microglobulin (B2m), accordingly to
RefFinder software analysis. The used primers are depicted
in Table 1.
Evaluation of protein expression by Western blotting
Membrane fractions were prepared as previously de-
scribed [28, 30, 31]. Liver and kidney samples were proc-
essed in the same way. The samples were homogenized
in buffer solution (100 mM Tris pH 7.5, 10 mM EDTA,
10 % SDS, 10 mM sodium fluoride, 10 mM sodium
pyrophosphate and 10 mM sodium orthovanadate); the
homogenate was centrifuged at 1,200 g (15 min), the
resulting supernatant was centrifuged at 12,000 g
(20 min), and the final pellet was suspended in the same
buffer as an enriched plasma membrane fraction. Soleus
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muscle samples were homogenized in the same buffer,
centrifuged at 760 g (10 min), and the supernatant was
directly used as a total membrane fraction (plasma
membrane and microsomes). Proximal small intestine
samples were homogenized in the same buffer, centri-
fuged at 3,000 g (10 min), the supernatant was centri-
fuged at 12,000 g (30 min); and the pellet was used as an
enriched plasma membrane fraction.
Total protein content in the samples was determined
by Bradford method (Bio-Rad Laboratories, Hercules,
CA, USA). Equal amounts of protein (40 to 60 μg, ac-
cordingly to the tissue) were electrophoresed, transferred
to nitrocellulose membrane and immunoblotted, accord-
ingly to the tissue, with anti-GLUT4 (EMD Millipore,
Billerica, MA, USA, #07-1404), anti-GLUT2 (EMD
Millipore, #07-1402), anti-SGLT1 (Millipore, #07-1417)
and anti-SGLT2 (Santa Cruz, Dallas, TX, USA, #98975)
antibodies. The appropriate secondary conjugated anti-
body was used accordingly to manufacturer specifica-
tions, followed by enhanced chemiluminescence (ECL)
procedure. The optical density of the blots was analyzed
using Image J software (National Institutes of Health,
Bethesda, MD, USA), and the densities of the respective
lanes, stained by Ponceau, were used for normalization.
The results were expressed as arbitrary units, related to
mean of the controls, which was set as 1.0.
Nuclear content of SIRT1
Nuclear proteins were extracted from liver samples as
previously described [5, 32]. Briefly, 0.3 g of liver tissue
was pulverized in nitrogen, and suspended in ice-cold
phosphate buffer saline with 0.2 mM dithiothreitol and
0.2 mM phenylmethylsulphonyl fluoride. After 1,000 g
centrifugation (10 min), the pellet was incubated in a
hypotonic buffer (10 min), followed by 12,000 g centrifu-
gation (1 min). The pellet was resuspended in a high salt
concentration buffer, incubated for 20 min, and centri-
fuged again at 12,000 g (2 min). The final supernatant
was recovered as the nuclear protein fraction. All pro-
cedure was performed at 4 °C, and the total protein
concentration of the samples was determined by the
Bradford method (Bio-Rad Laboratories). Samples were
stored at -80 °C for further analysis. Equal amounts of
nuclear proteins were subjected to immunodetection as
described above, using anti-SIRT1 antibody (Cell Signaling
Technology, MA, USA mAB#8469).
Statistical analysis
All data were expressed as mean ± standard error of the
mean (SEM). The results of four groups were matched by
one-way analysis of variance (ANOVA), with Student-
Newman-keuls as a post-test. Differences were considered
statistically significant at P < 0.05.
Results
Resveratrol improved glycemic control
Table 2 shows data related to the metabolic control. As
expected, blood glucose and plasma fructosamine concen-
trations, as well as 24-hour urinary glucose content were
significantly higher in diabetic rats (DP vs. ND, P < 0.001).
In both DI and DIR groups, there was a reduction in
blood glucose (P < 0.001) to levels similar to those ob-
served in non-diabetic rats. Glycosuria also decreased after
insulin treatment (DI vs. DP, P < 0.01), and resveratrol
induced an additional reduction (DIR vs. DI, P < 0.001),
although glycosuria still remained higher in comparison
to non-diabetic rats. Fructosamine concentration de-
creased in the DI group, and a further reduction was ob-
served with resveratrol (DIR vs. DI, P < 0.001), achieving
mean value similar to that observed in non-diabetic rats.
Slc2a4 and GLUT4 expression in soleus
To investigate the skeletal muscle regulation of glucose
disposal, and its participation in glycemic regulation, the
Slc2a4 mRNA and its GLUT4 protein were measured in
soleus muscle (Fig. 1). Both mRNA, and protein reduced
by ~55 % in muscles from diabetic rats (P < 0.01 vs.
ND). Insulin treatment restored both mRNA and pro-
tein expression, and resveratrol did not alter the effect
of insulin.
Table 1 Details for the primers and identification (ID) codes of the Taqman Gene Expression Assays used for real-time polymerase
chain reaction (qPCR)
Gene Primers sequence Dye Assay ID
Slc2a4 Sense: 5’-GGC TGT GCC ATC TTG ATG AC-3’ FAM AI5IQJM 186914021_1
Anti-sense: 5’-CAC GAT GGA CAC ATA ACT CAT GGA T-3’
Slc2a2 Inventoried FAM Rn00563565_m1
Pck1 Inventoried FAM Rn01529014_m1
G6pc Inventoried FAM Rn00689876_m1
B2m Inventoried FAM Rn00560865_m1
Slc2a4 solute carrier family 2 member 4, Slc2a2 solute carrier family 2 member 2, Pck1 phosphoenolpyruvate carboxykinase 1, G6pc glucose-6-phosphatase catalytic
subunit, B2m beta-2-microglobulin
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Resveratrol decreased GLUT2 expression in liver, but not
in intestine and kidney
To investigate other territorial fluxes of glucose which
could be involved in the resveratrol-induced whole-body
improvement of glycemic control, expression of glucose
transporters was evaluated in the proximal small
intestine (Fig. 2a and b), renal proximal tubule (Fig. 2c
and d), and liver (Fig. 2e). The GLUT2 expression did
not change in the proximal small intestine in any experi-
mental condition, as well as its correspondent luminal
sodium-glucose coupled transporter SGLT1. In renal
proximal tubule, DM increased GLUT2 (DP vs. ND, P <
0.05), an effect that was not significantly reversed by in-
sulin with or without resveratrol. Differently, the expres-
sion of the luminal SGLT2 in proximal tubule was
reduced by DM (DP vs. ND, P < 0.01), which also was
not altered by insulin with and without resveratrol. Fi-
nally, in liver, GLUT2 protein increased in response to
DM (DP vs. ND, P < 0.05), insulin treatment tended to
reduced it, but a significant reduction was observed only
with the administration of resveratrol to insulin therapy
(P < 0.01 vs. DP and P < 0.05 vs. DI).
Resveratrol regulates glucose metabolism markers in liver
Slc2a2 mRNA (Fig. 3a) was modulated exactly as the
GLUT2 protein in the liver. DM increased Slc2a2
mRNA, insulin treatment partially reduced it, but only
the adjunctive treatment with resveratrol restored it
to non-diabetic levels (DIR vs. DP, P < 0.001; DIR vs.
DI P < 0.05I).
The expression of Pck1 mRNA (Fig. 3b) was simi-
larly regulated. DM increased Pck1 mRNA (~3.2-fold,
P < 0.001 vs. ND), insulin treatment partially reduced
it (P < 0.001 vs. DP), and that was exacerbated with
resveratrol (P < 0.001 vs. DP; P < 0.05 vs. DI), which
brought mean expression to the level observed in
non-diabetic animals.
G6pc mRNA (Fig. 3d) tended to increase in diabetic
rats, and insulin therapy made that significant (DI vs.
ND, P < 0.05). Importantly, the resveratrol treatment
reversed the insulin-induced increase in G6pc mRNA
(DIR vs. DI, P < 0.05), restoring its expression to the
level observed in non-diabetic rats.
Finally, the hepatic glycogen content (Fig. 3d) was not
altered by insulin therapy, but was recovered by the
adjunctive treatment with resveratrol (P < 0.001 vs. DP;
P < 0.01 vs. DI), becoming higher than in non-diabetic
rats (P < 0.01 vs. ND).
Table 2 Characteristics of the non-diabetic (ND), diabetic rats treated with placebo (DP), with insulin (DI) and with insulin plus
resveratrol (DIR)
ND DP DI DIR
Body Weight (g) 416 ± 10.8 294 ± 15.7*** 354 ± 7.4**### 363 ± 9.5**###
Blood glucose (mg/dL) 125.2 ± 2.5 502.1 ± 18.7*** 140 ± 27.5### 153 ± 31.0###
Glycosuria (mg/24 h) 2.7 ± 0.9 234 ± 20.9*** 162 ± 23.7***## 59.2 ± 5.4*###§§§
Fructosamine (μMol/L) 98.7 ± 4.3 205 ± 11.0*** 138 ± 4.6**### 84.6 ± 11.3###§§§
Data are mean ± SEM of nine to ten animals, and were compared by one-way ANOVA, Student Newman-Keuls post test. *P < 0.05, **P < 0.01 and ***P < 0.001 vs ND;
##P < 0.01 and ###P < 0.001 vs DP; §§§P < 0.001 vs DI
Fig. 1 Slc2a4 mRNA (a) and GLUT4 protein (b) in soleus skeletal
muscle of non-diabetic (ND) and diabetic placebo- (DP), insulin- (DI)
and insulin plus resveratrol- (DIR) treated rats. AU, arbitrary units. Data
are mean ± SEM of four to six animals. **P < 0.01 vs ND; ##P < 0.01 and
###P < 0.001 vs DP. One-way analysis of variance (ANOVA),
Student-Newman-Keuls post-test
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Resveratrol increased nuclear SIRT1 content in liver
Resveratrol effects have been proposed to be mediated
by SIRT1, which, once activated in the nucleus, may
impair transcriptional activity. The nuclear content of
SIRT1 in the liver was unaltered in diabetic rats insulin-
treated or not (Fig. 4). However, the adjunctive treat-
ment with resveratrol induced a 3-fold increase in the
nuclear content of SIRT1 (DIR vs. all groups, P < 0.01).
Discussion
The present study was carried out to investigate if resvera-
trol would improve glycemic control in T1D-like rats
under insulin therapy. As expected, insulin treatment did
not completely restore glycemic control, because it is diffi-
cult to mimic endogenous insulin secretion [5], which is
also observed in T1D patients [33]. Resveratrol revealed a
powerful adjunctive effect, being able to induce a strong
additional reduction in glycosuria and to bring fructosa-
mine concentrations to values similar to those observed in
non-diabetic rats. This improvement in glycemic homeo-
stasis seems to be related to increased insulin sensitivity in
the liver, with a consequent reduction in glucose efflux.
Streptozotocin (STZ) treatment of rats is known to in-
duce a specific pancreatic beta cell necrosis, leading to
an insulinopenia syndrome [34], similar to the immuno-
logic induced beta cell necrosis in T1D human, except
Fig. 2 GLUT2 protein in proximal small intestine (a), renal proximal tubule (c) and in liver (e); SGLT1 protein in proximal intestine (b) and SGLT2
protein in renal proximal tubule (d) of non-diabetic (ND) and diabetic placebo- (DP), insulin- (DI) and insulin plus resveratrol- (DIR) treated rats. AU,
arbitrary units Data are mean ± SEM of five to nine animals. *P < 0.05, **P < 0.01 and ***P < 0.001 vs ND; ##P < 0.01 vs DP; §P < 0.05 vs DI. One-way
analysis of variance (ANOVA), Student-Newman-Keuls post-test
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by the extension of the beta cell lack, which is more pro-
nounced in humans.
Several reports have proposed that resveratrol improves
glycemic control in animals and humans with DM [11],
most of them conducted in T2D [11, 15, 17, 35]. Besides
improvement in insulin sensitivity, an improvement in
insulin secretion has also been reported to participate in
resveratrol effects [15, 16]. Thus, potential benefits of res-
veratrol in T1D should be limited. However, some studies
were performed in T1D-like STZ rats not treated with
insulin, and a resveratrol-induced effect was clearly
detected, such as reduction in blood glucose from 525 to
450 mg/dL [18] and from 469 to 373 mg/dL [19]. These
data highlight the insulin sensitizer effect of resveratrol,
but its use in T1D without concomitant insulin therapy
would be proscribed. Considering that, we evaluated res-
veratrol as adjunct to insulin therapy in T1D, which has
never been investigated.
The present results revealed the impressive effect of
resveratrol as adjunct to insulin therapy in T1D-like rats
based on fructosamine decay. The serum fructosamine
includes all glycated plasmatic proteins produced over
the last 2-3 weeks, reflecting recent changes in glycemic
control. Since peripheral insulin concentration is un-
changeable in this T1D model, the glucose-lowering
effect must have been achieved due to changes in one or
Fig. 3 Slc2a2 (a) Pck1 (b) and G6pc (c) mRNA expression and glycogen content (d) in liver of non-diabetic (ND) and diabetic placebo- (DP),
insulin- (DI) and insulin plus resveratrol- (DIR) treated rats. AU, arbitrary units. Data are mean ± SEM of five to seven animals. *P < 0.05 and ***P < 0.001
vs ND; ###P < 0.001 vs DP; §P < 0.05 vs DI; ƒƒP < 0.01 vs all groups. One-way analysis of variance (ANOVA), Student-Newman-Keuls post-test
Fig. 4 Nuclear SIRT1 protein in liver of non-diabetic (ND) and diabetic
placebo- (DP), insulin- (DI) and insulin plus resveratrol- (DIR) treated
rats. AU, arbitrary units. Data are mean ± SEM of 3 animals.
ƒƒP < 0.01 vs all groups. One-way analysis of variance (ANOVA),
Student-Newman-Keuls post-test
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more peripheral flux of glucose, which invariably is
accompanied by changes in the glucose transporters
expression.
Participation of improved skeletal muscle glucose uptake
by resveratrol has already been proposed. Piceatannol, a
metabolite of resveratrol, was shown to increase AMPK
phosphorylation, GLUT4 translocation, and glucose up-
take in L6 myocytes [12]. Besides, in muscle from 2-week
STZ-diabetic rats not receiving insulin, 7-day resvera-
trol treatment increased soleus GLUT4 content to a value
similar to that observed in insulin-treated animals [14].
We observed a decreased Slc2a4/GLUT4 expression in
diabetic rats, and that was completely recovered by insulin
treatment, as reported elsewhere [5, 36]. Resveratrol ad-
ministration did not modify muscle Slc2a4/GLUT4 ex-
pression in comparison to insulin alone, showing that, as
adjunctive therapy in T1D, this compound does not im-
prove glucose clearance by skeletal muscle.
SGLT1- and GLUT2-related increase in intestinal glu-
cose absorption has been proposed in T2D patients [37]
and 2-week STZ-diabetic rats [38]. However, modulation
in SGLT1 and/or GLUT2 in T1D-like long-term models
has never been clearly reported. In the present study, we
did not observe alterations in either SGLT1 or GLUT2
proteins in diabetic rats, regardless of the treatment
employed, suggesting that modifications in the intestinal
glucose absorption rate do not contribute to the ob-
served changes in glycemic homeostasis induced by
resveratrol. We did not find previous studies which eval-
uated the effects of resveratrol in intestinal SGLT1 and
GLUT2 expression.
It has been extensively reported that inhibition of renal
glucose reabsorption by SGLT2 inhibitors contributes to
blood glucose reduction, and that is a recent therapeutic
approach to DM treatment [27]. STZ-diabetic rats re-
vealed increased Slc5a2 mRNA expression [39]; however,
SGLT2 protein expression was not investigated. On the
other hand, in mice, DM-induced regulation of SGLT2 is
controversial, being reduced in STZ-diabetic mice, but
increased in db/db and Akita mice [40], pointing out to
the complexity of this regulation. In the present study,
7 weeks of DM duration in STZ-diabetic rats decreased
SGLT2, and neither insulin nor insulin plus resveratrol
altered this pattern of expression. Differently, GLUT2
has been clearly described to increase after 4 weeks of
DM [28, 31], as observed here; and insulin reversed this
effect. Overall, since resveratrol altered neither SGLT2
nor GLUT2 expression, there is no data to support a
resveratrol-induced reduction in renal glucose reabsorp-
tion, which could contribute to improving glycemic
control.
Relevant results were obtained in the liver. GLUT2
protein increased in diabetic rats and was partially re-
duced by insulin therapy, in agreement with previous
work [31]. Remarkably, the adjunctive treatment with
resveratrol promoted a further decrease in GLUT2 con-
tent, restoring the protein levels to those of non-diabetic
rats. Besides, parallel regulations were detected in Slc2a2
mRNA expression, indicating a transcriptional modula-
tion. Since a reduction in GLUT2 expression has been
related to reduced hepatic glucose efflux in several con-
ditions, such as the Fanconi-Bickel syndrome [41] and
the Foxa3-/- mice [42], this result points out the hepatic
territory as responsible for the beneficial effects of
resveratrol.
To deepen the investigation of liver participation,
some markers of glucose metabolism, which have been
related to impaired glycemic homeostasis in DM [43],
were analyzed. The expression of the pivotal gluconeo-
genic enzyme Pck1, which increased in DM, was only re-
stored to non-diabetic levels by treatment with insulin
plus resveratrol. G6pc expression tended to increase in
DM, and insulin therapy did not reverse this effect, as it
was expected, considering the repressor effect of insulin
on G6pc gene [44]. However, the resveratrol treatment
restored the G6pc expression to the non-diabetic levels.
These findings reveal the resveratrol-induced increase in
the local insulin sensitivity, and anticipate a reduction in
hepatic glucose production and efflux [45, 46]. Indeed,
in the liver of diabetic rats not treated with insulin, resver-
atrol was reported to increase the insulin signaling path-
way activity [47], and restored PEPCK expression [14] and
G6Pase activity [48]. However, resveratrol effect upon
hepatic glucose metabolism, as adjunctive therapy to
insulin in T1D had never been previously investigated.
Increased deacetylase activity of SIRT1 was extensively
proposed as the major mechanism by which resveratrol
induces beneficial effects in several tissues [11]. How-
ever, in the liver, this effect was far from being demon-
strated. Indeed, in the liver of STZ-diabetic rats not
receiving insulin, resveratrol increased Sirt1 mRNA [18],
but had no significant effect on the cytosolic protein
[49]; besides, in the liver of insulin resistant KKAy mice,
an increase in SIRT1 protein, supposedly measured in a
homogenate, was reported to be increased in only one
mouse [50]. We are showing for the first time a
resveratrol-induced robust increase in nuclear SIRT1
protein, which might be involved in the regulation of the
hepatic glucose metabolism-related genes investigated.
Interestingly, despite proposals that resveratrol-induced
improvement in glycemic homeostasis could involve sup-
pression of gluconeogenic enzymes expression [11, 48],
and that this effect could be mediated by increased SIRT1
activity [11, 18, 49, 50], previous studies suggested the
opposite. Activation of SIRT1 in isolated hepatocytes was
reported to increase [51], whereas SIRT1 knockdown in
mice was reported to decrease [52] the expression of key
gluconeogenic enzymes. Thus, it remains to be further
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investigated whether there is a cause-effect relationship
between increased nuclear SIRT1 and decreased Pck1/
G6pc expression in the liver of T1D-like rats receiving res-
veratrol plus insulin.
SIRT1-mediated decrease of insulin resistance has
been proposed, mainly based on resveratrol treatment
[11, 50], although the participation of SIRT1 as a nuclear
deacetylase is far from being clearly demonstrated in
these studies. In the present study, the resveratrol-
induced amelioration of glycemic control depicts im-
provement of insulin sensitivity, since the T1D animals
were submitted to the same insulin regimen. Besides,
the improvement in insulin sensitivity was observed in
liver, where regulation of genes related to glucose metab-
olism was observed, together with increased nuclear
content of SIRT1. Thus, for the first time, the insulin
sensitizer effect of SIRT1 deacetylase can be rationally
proposed.
Conclusion
In conclusion, resveratrol was able to improve glycemic
control in insulin-treated T1D-like rats. This effect
seems not to involve changes in glucose fluxes in the
small intestine, renal proximal tubule, and soleus skeletal
muscle; but to be related to several changes in the liver,
where downregulation of Slc2a2/GLUT2, Pck1 and G6pc
expression was observed, favoring reduction of glucose
production and efflux. Besides, resveratrol increased
SIRT1 nuclear protein content in liver, which may be re-
lated to the observed gene expression regulations.
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